Document is current
Any future updates will be listed below
-
Authors
Liu, Jianhua
Chen, Hao
Qiao, Guibin
Zhang, Jia-Tao
Zhang, Shuaitong
Zhu, Changbin
Chen, Yu
Tang, Jiming
Li, Weiwei
Wang, Siyun
Tian, Hongxia
Chen, Zhihong
Ma, Dong
Tian, Jie
Wu, Yi-Long
-
Funding
Funding for this research was provided by:
the Research Start-up Funds for National Natural Science Foundation of China (8200110771)
the Key Lab System Project of Guangdong Science and Technology Department, Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (2017B030314120)
Guangdong Provincial People's Hospital Scientific Research Funds for Leading Medical Talents in Guangdong Province (KJ012019426)
- License Information
-
More Information
Article History
Received: 29 June 2022
Accepted: 29 August 2022
First Online: 19 September 2022
Declarations
:
: Yi-Long Wu declares speaker fees from AstraZeneca, Eli Lilly, Pfizer, Roche, and Sanofi. Weiwei Li and Changbin Zhu were employed by Amoy Diagnostics Co., Ltd. None of the other authors have any conflicts of interest to declare.
: The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Research Ethics Committee of Guangdong Provincial People's Hospital (No. KY-Z-2022–006-02). All subjects gave their informed consent for inclusion before they participated in this study.
